0001415889-22-012301.txt : 20221209
0001415889-22-012301.hdr.sgml : 20221209
20221209160721
ACCESSION NUMBER: 0001415889-22-012301
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221207
FILED AS OF DATE: 20221209
DATE AS OF CHANGE: 20221209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KELER TIBOR
CENTRAL INDEX KEY: 0001429931
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 221454837
MAIL ADDRESS:
STREET 1: 30 PARK ROAD
CITY: OTTSVILLE
STATE: PA
ZIP: 18942
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
form4-12092022_091203.xml
X0306
4
2022-12-07
0000744218
Celldex Therapeutics, Inc.
CLDX
0001429931
KELER TIBOR
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
false
true
false
false
EXECUTIVE VP & CSO
Common Stock, par value $0.001 per share
2022-12-07
4
M
0
16860
2.78
A
24217
D
Common Stock, par value $0.001 per share
2022-12-07
4
S
0
16860
36.9283
D
7357
D
Incentive Stock Option (right to buy)
2.78
2022-12-07
4
M
0
16860
0
D
2029-06-19
Common Stock
16860
43140
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $37.28 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Samuel B. Martin, attorney-in-fact for Tibor Keler
2022-12-09